Abstracts tagged "longitudinal studies and rheumatoid arthritis (RA)"

Abstract Number: 2489 • 2018 ACR/ARHP Annual Meeting
In Clinical Practice a Substantial Group of Rheumatoid Arthritis (RA) Patients on Biologic Therapy (bDMARDs) Has Persistent Moderate Disease Activity Despite Treatment Switches That Correlates with Unfavourable Long-Term Outcome
Irini Genitsaridi^1,2, Irini Flouri³, Argyro Repa², Nestor Avgoustidis², Nikolaos Kougkas², Ioannis Papalopoulos², Styliani Polia², Konstantinos Marias¹, Dimitris Plexousakis⁴, George Bertsias² and Prodromos Sidiropoulos², ¹Computational BioMedicine Laboratory, Institute of Computer Science, Foundation for Research and Technology-Hellas, Heraklio, Greece, ²Department of Rheumatology, Clinical Immunology and Allergy, University of Crete, School of Medicine, Heraklion, Greece, ³Department of Rheumatology, Clinical Immunology and Allergy, University of Crete, School of Medicine, Heraklio, Greece, ⁴Information Systems Laboratory, Institute of Computer Science, Foundation for Research and Technology-Hellas, Heraklio, Greece
Background/Purpose: Registry data have shown that treatment with bDMARDs induces remission or LDA (RLDA) in up-to 50% of RA patients. Approximately 30-50% of patients have…
Abstract Number: 538 • 2017 ACR/ARHP Annual Meeting
Severe Adverse Drug Reactions Due to Disease Modifying Drugs in Patients with Incident Rheumatoid Arthritis
Lydia A Alcazar¹, Judit Font Urgelles², Cynthia Milagros León Cárdenas², Cristina Vadillo Font², Dalifer Freites Núñez¹, Leticia Leon¹, Juan A Jover Jover² and Zulema Rosales Rosado^1,2, ¹Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain, ²Rheumatology, Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose: There is a well-known risk of developing adverse drug reactions (ADR) in rheumatology due, mainly, to the Disease Modifying Drugs (DMARD) used. It is…
Abstract Number: 1443 • 2017 ACR/ARHP Annual Meeting
Adverse Drug Reactions Due to Disease Modifying Drugs in a Cohort of Patients with Incident Rheumatoid Arthritis
Zulema Rosales Rosado^1,2, Dalifer Freites Núñez², Cristina Lajas Petisco¹, Esperanza Pato Cour¹, Leticia Leon², Judit Font Urgelles¹, Juan A Jover Jover¹ and Lydia A Alcazar², ¹Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ²Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain
Background/Purpose: There is a well-known risk of developing adverse drug reactions (ADR) in rheumatology due, mainly, to the Disease Modifying Drugs (DMARD) used. After more…
Abstract Number: 1 • 2016 ACR/ARHP Annual Meeting
Factors Predicting Likelihood of Remaining Positive for Rheumatoid Arthritis-Related Autoantibodies Following Autoantibody Screening
Jill M. Norris¹, Elizabeth A. Bemis¹, M. Kristen Demoruelle², Michael Weisman³, Jane H. Buckner⁴, Peter K. Gregersen⁵, Ted R Mikuls⁶, James R. O'Dell⁶, Richard M. Keating⁷, Kevin D. Deane⁸ and V. Michael Holers⁸, ¹Epidemiology, Colorado School of Public Health, Aurora, CO, ²Rheumatology, University of Colorado School of Medicine, Aurora, CO, ³Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁴Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁵Feinstein Insititute for Medical Research, Manhasset, NY, ⁶Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁷Division of Rheumatology, Scripps Health, La Jolla, CA, ⁸Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: RA-related autoantibodies are typically elevated prior to the onset of RA. Screening for autoantibody (aAb) positive individuals is a means to assemble a cohort…
Abstract Number: 2658 • 2016 ACR/ARHP Annual Meeting
Adverse Drug Reactions Due to Disease Modifying Drugs in Patients with Rheumatoid Arthritis
Zulema Rosales Rosado^1,2, Judit Font Urgelles¹, Dalifer Freites Núñez¹, Cynthia Milagros León Cárdenas¹, Cristina Lajas Petisco¹, Leticia Leon², Luis Rodriguez Rodriguez², Juan A Jover Jover¹ and Lydia Abásolo Alcázar², ¹Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ²Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain
Background/Purpose: There is a high risk of developing adverse drug reactions (ADR) in rheumatology due, mainly, to the Disease Modifying Drugs (DMARD) used. After more…
Abstract Number: 36 • 2015 ACR/ARHP Annual Meeting
The Incidence of Cardiovascular Events in Patients with Rheumatoid Arthritis: a 15 Years Observational Cohort Study
Koen Laan¹, Rabia Agca^1,2, Alexandre E. Voskuyl³, Maarten Boers², Willem Lems² and Mike T. Nurmohamed^1,2, ¹Rheumatology, Amsterdam Rheumatology and immunology Center, Reade, Amsterdam, Netherlands, ²Rheumatology, Amsterdam Rheumatology and immunology Center, VU University medical center, Amsterdam, Netherlands, ³Rheumatology, Amsterdam Rheumatology and immunology Center, location VU University medical center, Amsterdam, Netherlands
Background/Purpose: The increased risk for cardiovascular (CV) disease in rheumatoid arthritis (RA) is well established. However, there are relatively few contemporary cohort studies with long…
Abstract Number: 513 • 2015 ACR/ARHP Annual Meeting
Cumulative Association of Genetic Variants with Rheumatoid Joint Damage Progression in Mexican Americans and European Americans
Rector Arya¹, Inmaculada del Rincon², Jose Felix Restrepo³, Vidya S Farook⁴, Christopher P Jenkinson⁵, Ravindranath Duggirala⁶ and Agustin Escalante⁷, ¹Pediatrics, University of Texas Health Science Center at San Antonio, San Antonio, TX, ²Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, ³Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX, ⁴Genetics, Texas Biomedical Research Institute, San Antonio, TX, ⁵University of Texas Health Science Center at San Antonio, San Antonio, TX, ⁶Regional Academic Health Center, Harlingen, TX, ⁷Dept. of Medicine-Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX
Background/Purpose: Genealogical and genetic association studies have suggested that joint damage in rheumatoid arthritis (RA) may be heritable. We and others have found a number…
Abstract Number: 1382 • 2014 ACR/ARHP Annual Meeting
The Longitudinal Course of Fatigue in Rheumatoid Arthritis – Results from the Norfolk Arthritis Register
Katie L Druce¹, Gareth T Jones², Gary J. Macfarlane¹, Suzanne M. Verstappen³ and Neil Basu¹, ¹Musculoskeletal Research Collaboration (Epidemiology Group), University of Aberdeen, Aberdeen, United Kingdom, ²Musculoskeletal Research Collaboration (Epidemiology Group),, University of Aberdeen, Aberdeen, United Kingdom, ³Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom
Background/Purpose: Fatigue is common and burdensome in Rheumatoid Arthritis (RA). Though RA fatigue progression varies significantly between individuals, to date, published analyses have only considered…
Abstract Number: 2759 • 2013 ACR/ARHP Annual Meeting
Can RA Registries Provide Contextual Safety Data For Modern RCTs?
Kaleb Michaud¹, Johan Askling², Hisashi Yamanaka³, Deborah Symmons⁴, Marie Holmqvist², Thomas Frisell⁵, George Reed⁶, Dimitrios A. Pappas⁷, Eiichi Tanaka⁸, Eisuke Inoue⁹, Suzanne M.M. Verstappen⁴, Christopher Garwood⁴, Laura Horne¹⁰, Kathy Lampl¹¹, Niklas Berglind¹², Stefan Franzen¹², Fredrik Nyberg¹³, Trung Tran¹⁴, Meilien Ho¹⁵ and Jeffrey D. Greenberg¹⁶, ¹Rheumatology, National Data Bank for Rheumatic Diseases & University of Nebraska Medical Center, Omaha, NE, ²Karolinska Institutet, Stockholm, Sweden, ³Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁴Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, ⁵Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁶Orthopedics, University of Massachusetts Medical School, Worcester, MA, ⁷Columbia University, New York, NY, ⁸Tokyo Women's Medical University, Tokyo, Japan, ⁹Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, ¹⁰AstraZeneca, Wilmington, DE, ¹¹AstraZeneca R&D Wilmington, Wilmington, DE, ¹²AstraZeneca R&D Mölndal, Mölndal, Sweden, ¹³AstraZeneca R&D, Mölndal, Sweden, ¹⁴MedImmune LLC, Gaithersburg, MD, ¹⁵AstraZeneca R&D Alderley Park, Macclesfield, United Kingdom, ¹⁶New York University School of Medicine, New York, NY
Background/Purpose: For ethical reasons, modern phase-III RCTs in rheumatoid arthritis (RA) have limited placebo exposure time, resulting in uncertainties when interpreting low frequency adverse events…
Abstract Number: 1267 • 2012 ACR/ARHP Annual Meeting
Inflammatory Burden Predicts Progression of Carotid Plaque in Rheumatoid Arthritis: A 24-Month Longitudinal Analysis
Churl Hyun Im¹, Na Ri Kim¹, Jong Wan Kang¹, Young Ji Kim¹, Kyung Hye Kim¹, Eon Jeong Nam¹ and Young Mo Kang², ¹Internal Medicine (Rheumatology), Kyungpook National University School of Medicine, Daegu, South Korea, ²Department of Internal Medicine (Rheumatology), Kyungpook National University School of Medicine, Daegu, South Korea
Background/Purpose: Carotid atherosclerosis, which is associated with the increased risk of cardiovascular (CV) disease, is increased in rheumatoid arthritis (RA) patients. In our previous study,…
Abstract Number: 1232 • 2012 ACR/ARHP Annual Meeting
Association of Actometer Assessed Physical Activity and Fatigue in Patients with Rheumatoid Arthritis: Patients with a Lower Daily Activity Have More Fatigue
Sanne van Dartel¹, Han Repping-Wuts¹, Dewy van Hoogmoed¹, Hans Knoop², Gijs Bleijenberg¹, Piet L.C. van Riel³ and J. Fransen³, ¹Reumatology 470, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Nijmegen Expert Centre of Chronic Fatigue, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ³Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
Background/Purpose: Fatigue in rheumatoid arthritis (RA) is related to pain and disability, and several psycho-social factors such as coping strategies. In Chronic Fatigue Syndrome (CFS),…
Abstract Number: 827 • 2012 ACR/ARHP Annual Meeting
Sustained Development of Cardiovascular Disease in Rheumatoid Arthritis Despite Cardioprotective Treatment: The 10-Year Prospective Carre-Study
Alper M. van Sijl¹, Inge A.M. van den Oever¹, Mike J.L. Peters², Vokko P. van Halm³, Alexandre E. Voskuyl⁴, Yvo M. Smulders⁵ and Mike T. Nurmohamed¹, ¹Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ²Internal medicine, VU University Medical Center, Amsterdam, Netherlands, ³Cardiology, Academic Medical Centre, Amsterdam, Netherlands, ⁴Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ⁵Internal Medicine, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory joint disease which is associated with an increased cardiovascular (CV) risk. It is still unknown to what…
Abstract Number: 501 • 2012 ACR/ARHP Annual Meeting
TNF Inhibitor Treatment in Rheumatoid Arthritis (RA) Patients with Moderate Versus High Disease Activity At Baseline: A Comparison of Utility Gains, Response and Remission Rates
Elisabeth Lie, Siri Lillegraven, Karen M. Fagerli, Till Uhlig and Tore K. Kvien, Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: Randomized clinical trials in RA have until recently focused on patients (pts) with high disease activity, but the majority of pts in the clinic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].